Alternatives to Otezla If You Can't Fill Your Prescription

Not being able to fill your Otezla prescription — whether due to insurance denial, cost, prior authorization delays, or specialty pharmacy complications — is a frustrating but common experience. The good news is that there are several effective alternatives for the conditions Otezla treats: plaque psoriasis, psoriatic arthritis (PsA), and Behçet's disease. The right alternative depends on your specific condition, disease severity, insurance coverage, and how you weigh factors like cost, route of administration, and potential side effects. Here's a thorough look at your options.

Understanding What Otezla Does — And Why It Matters for Alternatives

Otezla (apremilast) is an oral PDE4 inhibitor. It works by blocking the PDE4 enzyme inside immune cells, which raises cyclic AMP (cAMP) levels and reduces the inflammatory signals that drive psoriasis and psoriatic arthritis. Unlike biologics, which target specific proteins outside cells (like TNF-alpha or interleukins), Otezla works intracellularly. This makes it less potent than most biologics, but also means it doesn't suppress the immune system as aggressively — a real advantage for some patients.

Otezla is oral (pill form) and requires no lab monitoring — two features patients often value. When looking for alternatives, consider whether you want to stay with oral medications or are open to injectables, and how much lab monitoring and follow-up you're able to manage.

Alternative 1: Methotrexate — The Affordable Oral Option

Methotrexate is one of the oldest and most widely used treatments for both plaque psoriasis and psoriatic arthritis. It's a disease-modifying antirheumatic drug (DMARD) that works by inhibiting folic acid metabolism, reducing the rapid skin cell turnover that causes psoriatic plaques, and suppressing joint inflammation. It's taken once weekly — either as a tablet or injection.

The biggest advantage of methotrexate is cost: generic methotrexate is available for under $30 per month at most pharmacies, making it dramatically more affordable than Otezla. Many insurance plans actually require a trial of methotrexate before approving Otezla (step therapy). The downside is that methotrexate requires regular liver function tests and blood counts, and can cause nausea, fatigue, and mouth sores in some patients. Folic acid supplementation is typically taken alongside it to reduce side effects.

Best for: Patients who need an affordable oral option and are comfortable with periodic lab monitoring. Also a good option when insurance coverage for Otezla has been denied.

Alternative 2: Deucravacitinib (Sotyktu) — The Newer Oral Option

Deucravacitinib (brand name Sotyktu), approved by the FDA in 2022, is a TYK2 (tyrosine kinase 2) inhibitor — a different mechanism from Otezla but still an oral small molecule. It targets the IL-23 and IL-12 signaling pathways that play a central role in psoriatic inflammation. It's approved specifically for adults with moderate-to-severe plaque psoriasis and is taken once daily.

Clinical trial data suggests Sotyktu may offer better skin clearance rates than Otezla for plaque psoriasis — making it potentially a more effective oral alternative for patients with significant skin involvement. Like Otezla, it's a specialty medication with a high list price and insurance prior authorization requirements. It does not currently have an FDA indication for psoriatic arthritis, so it's specifically an option for psoriasis patients.

Best for: Patients with plaque psoriasis (not PsA or Behçet's) who want an oral option that may be more effective than Otezla. Requires specialty pharmacy access like Otezla.

Alternative 3: Adalimumab (Humira) and Biosimilars — The Injectable Biologic

Adalimumab (brand name Humira) is a TNF-alpha inhibitor biologic that has been used for psoriasis and psoriatic arthritis for over two decades. It's given as a subcutaneous injection (under the skin) every 2 weeks. Since 2023, multiple FDA-approved adalimumab biosimilars have entered the US market — including Hadlima, Hyrimoz, Cyltezo, and others — at significantly lower cost than the original brand-name Humira.

For patients with both psoriasis and psoriatic arthritis, adalimumab and its biosimilars are effective for both conditions. The main drawback compared to Otezla is that it requires injections and carries a slightly higher risk of infections due to more significant immunosuppression. Lab monitoring (for tuberculosis screening and periodic labs) is required.

Best for: Patients with moderate-to-severe psoriasis or active psoriatic arthritis who need stronger efficacy and are open to injectable therapy. Biosimilars can reduce cost substantially.

Alternative 4: Secukinumab (Cosentyx) — High-Efficacy Biologic

Secukinumab (Cosentyx) is an IL-17A inhibitor biologic approved for plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. Clinical trials have consistently shown it achieves very high rates of skin clearance — 90% clearance (PASI 90) — in many patients with moderate-to-severe psoriasis, making it generally more effective than Otezla for skin disease. It's given by subcutaneous injection — weekly for the first 5 weeks, then monthly.

Best for: Patients with moderate-to-severe plaque psoriasis or psoriatic arthritis who want maximum skin clearance and are comfortable with injectable therapy.

Alternative 5: Ustekinumab (Stelara) — The Less Frequent Injection

Ustekinumab (Stelara) is an IL-12/23 inhibitor biologic approved for both psoriasis and psoriatic arthritis. One of its biggest advantages is dosing convenience: after the initial loading dose, it's given every 12 weeks by injection. For patients who want a biologic option but find monthly injections burdensome, this quarterly schedule can be appealing. Note that biosimilars for ustekinumab have entered the US market and may offer cost advantages.

How to Choose the Right Alternative

The best alternative to Otezla depends on several factors. Consider the following:

Your condition: Psoriasis only? Psoriatic arthritis? Behçet's disease? Not all alternatives treat all three conditions. Sotyktu, for example, is only FDA-approved for psoriasis.

Disease severity: Mild-to-moderate disease may respond well to methotrexate or Sotyktu. Severe or rapidly progressing disease may warrant a biologic like Cosentyx.

Cost and insurance: Methotrexate is by far the most affordable. Biologics and Sotyktu are expensive specialty medications. Adalimumab biosimilars have brought biologic costs down significantly.

Route of administration: If you prefer pills over injections, methotrexate or Sotyktu are your oral options. All biologics are injectable.

Lab monitoring tolerance: Otezla requires no routine lab monitoring. Methotrexate requires regular blood tests. Biologics require TB screening and periodic labs.

Still Trying to Access Otezla?

If you're exploring alternatives primarily because of access barriers — not because Otezla isn't right for you — medfinder may be able to help. medfinder contacts pharmacies on your behalf to find which ones can fill your prescription, saving you the time and frustration of hunting yourself. You can also read our guide on Why Is Otezla So Hard to Find? to understand the structural barriers and how to overcome them.